Header Logo

Connection

SUSAN BLANEY to Area Under Curve

Back to Details
This is a "connection" page, showing publications SUSAN BLANEY has written about Area Under Curve.
SUSAN BLANEY
Connection Strength
0.912
Area Under Curve
  1. A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112). Clin Cancer Res. 2013 Dec 01; 19(23):6578-84.
    View in: PubMed
    Score: 0.103
  2. Plasma and cerebrospinal fluid pharmacokinetics of MP470 in non-human primates. Cancer Chemother Pharmacol. 2011 Apr; 67(4):809-12.
    View in: PubMed
    Score: 0.082
  3. Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates. Cancer Chemother Pharmacol. 2008 Apr; 61(4):647-52.
    View in: PubMed
    Score: 0.066
  4. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. Cancer Chemother Pharmacol. 2007 Mar; 59(4):461-6.
    View in: PubMed
    Score: 0.062
  5. Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates. Clin Cancer Res. 2005 Aug 15; 11(16):5981-3.
    View in: PubMed
    Score: 0.059
  6. Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates. Cancer Chemother Pharmacol. 2004 Aug; 54(2):127-30.
    View in: PubMed
    Score: 0.054
  7. Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates. Cancer Chemother Pharmacol. 2004 Jul; 54(1):85-8.
    View in: PubMed
    Score: 0.053
  8. Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates. Cancer Chemother Pharmacol. 2004 Jun; 53(6):527-32.
    View in: PubMed
    Score: 0.053
  9. Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates. Cancer Chemother Pharmacol. 2004 Jan; 53(1):39-42.
    View in: PubMed
    Score: 0.052
  10. Influence of phenytoin on the disposition of irinotecan: a case report. J Pediatr Hematol Oncol. 2002 Feb; 24(2):130-3.
    View in: PubMed
    Score: 0.046
  11. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. Cancer Chemother Pharmacol. 1998; 41(6):464-8.
    View in: PubMed
    Score: 0.035
  12. Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. Childs Nerv Syst. 2015 Aug; 31(8):1283-9.
    View in: PubMed
    Score: 0.029
  13. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. J Clin Oncol. 2011 Jan 20; 29(3):324-9.
    View in: PubMed
    Score: 0.021
  14. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer. 2010 Apr; 54(4):538-45.
    View in: PubMed
    Score: 0.020
  15. Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. Cancer Chemother Pharmacol. 2010 Feb; 65(3):419-25.
    View in: PubMed
    Score: 0.019
  16. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol. 2008 Oct 20; 26(30):4921-7.
    View in: PubMed
    Score: 0.018
  17. Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study. Neuro Oncol. 2008 Oct; 10(5):752-8.
    View in: PubMed
    Score: 0.018
  18. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group. Cancer Chemother Pharmacol. 2008 Nov; 62(6):1027-37.
    View in: PubMed
    Score: 0.017
  19. Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study. Clin Cancer Res. 2008 Feb 15; 14(4):1124-30.
    View in: PubMed
    Score: 0.017
  20. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2008 Jan 20; 26(3):399-405.
    View in: PubMed
    Score: 0.017
  21. Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer. J Clin Oncol. 2004 Nov 01; 22(21):4394-400.
    View in: PubMed
    Score: 0.014
  22. Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study. Clin Cancer Res. 2004 Aug 01; 10(15):5072-5.
    View in: PubMed
    Score: 0.014
  23. Phase I trial of rebeccamycin analog (NSC #655649) in children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol. 2003 Jul; 25(7):526-33.
    View in: PubMed
    Score: 0.013
  24. Pharmacokinetics of intrathecal gemcitabine in nonhuman primates. Clin Cancer Res. 2002 Jul; 8(7):2437-42.
    View in: PubMed
    Score: 0.012
  25. Pharmacokinetics and cerebrospinal fluid penetration of CI-994 (N-acetyldinaline) in the nonhuman primate. Clin Cancer Res. 2000 Mar; 6(3):994-7.
    View in: PubMed
    Score: 0.010
  26. Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer. J Clin Oncol. 1997 Nov; 15(11):3330-7.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.